Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 110.49 0.75 (0.68%) Market Cap: 6.97 Bil Enterprise Value: 10.88 Bil PE Ratio: 22.78 PB Ratio: 1.88 GF Score: 78/100

Jazz Pharmaceuticals PLC at Piper Jaffray Healthcare Conference Transcript

Dec 03, 2019 / 01:00PM GMT
Release Date Price: $146.45 (-2.61%)
David A. Amsellem
Piper Jaffray Companies, Research Division - MD and Senior Research Analyst

Okay. Let's get started. This is David Amsellem from the Piper Jaffray specialty pharma team. I'm delighted to kick off with our portion of the 31st Annual Piper Jaffray Healthcare Conference. Our first fireside chat is Jazz Pharmaceuticals, and we're delighted to have senior management with us today, Bruce Cozadd, CEO; and Rob Iannone, EVP, Head of R&D. So thank you both for joining us. I'll kick it over to you, Bruce, for maybe a couple of quick remarks, and then we can dive right into what at least will be for me a lot of questions.

Bruce C. Cozadd
Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO

Yes. So thank you, David. Good to be back. And let me start with the least interesting thing I'm going to say all day, which is we will make forward-looking statements, non-GAAP to GAAP reconciliations of all the figures I mentioned are on our website. And if I refer to guidance, I'm referring guidance to -- I'm referring to guidance we gave on our last

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot